ClinicalTrials.gg

Program

galunisertib

Also written as “Galunisertib”, “LY2157299” and “Galunisertib + Nerandomilast Combination”.

Its studies are mostly in Carcinoma, Hepatocellular · Pancreatic Neoplasms · Neoplasms · Amyotrophic Lateral Sclerosis · Glioblastoma, led by 2 companies.

Furthest: phase 3, since Dec 6, 201316 company-led studies, 1 open or runningNext primary completion: Jun 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly150 open or runningphase 3since Dec 6, 2013Nov 1, 2010none ahead
Gipfel Life Sciences11 open or runningphase 3since Jan 2, 2026Jan 2, 2026Jun 30, 2027phase 3 · NCT07321860

Also a collaborator on its studies: Bristol-Myers Squibb and AstraZeneca.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 1 study since Nov 1, 2010.

  1. Jun 9, 2011Phase 2 study in NeoplasmsEli Lilly · NCT01373164 · 170 enrolled · United States, Belgium, France and more
  2. Apr 19, 2012Phase 2 study in GlioblastomaEli Lilly · NCT01582269 · 158 enrolled · United States, Australia, Belgium and more
  3. Sep 6, 2012Phase 1 study in GliomaEli Lilly · NCT01682187 · 66 enrolled · United States, Spain
  4. Nov 5, 2012Phase 1 study in NeoplasmsEli Lilly · NCT01722825 · 12 enrolled · Japan
  5. Dec 6, 2012Phase 1 study in Healthy VolunteersEli Lilly · NCT01746004 · 8 enrolled · United States
  6. Oct 16, 2013Phase 1 study in Healthy VolunteersEli Lilly · NCT01965808 · 16 enrolled · United States
  7. Dec 6, 2013Phase 3 study in Myelodysplastic SyndromesEli Lilly · NCT02008318 · 43 enrolled · Germany, Italy, Spain
  8. May 14, 2014Phase 1 study in Pancreatic NeoplasmsEli Lilly · NCT02154646 · 6 enrolled · Japan
  9. Jun 12, 2014Phase 2 study in Carcinoma, HepatocellularEli Lilly · NCT02178358 · 132 enrolled · China, Hong Kong, Korea, Republic of and more
  10. Sep 11, 2014Phase 1 study in Carcinoma, HepatocellularEli Lilly · NCT02240433 · 9 enrolled · Japan
  11. Nov 26, 2014Phase 1 study in NeoplasmsEli Lilly · NCT02304419 · 10 enrolled · United States
  12. Apr 17, 2015Phase 2 study in Solid TumorEli Lilly · NCT02423343 · 41 enrolled · United States, Spain
  13. Apr 6, 20162 phase 1 studiesEli Lilly · NCT02734160, NCT02752919
  14. Jan 2, 2026Gipfel Life Sciences's first study: phase 3 study in Amyotrophic Lateral SclerosisNew to Gipfel Life SciencesGipfel Life Sciences · NCT07321860 · 60 planned

Ahead

  1. Jun 30, 2027Primary completion: phase 3 study in Amyotrophic Lateral SclerosisGipfel Life Sciences · NCT07321860

TargetBeta

TGFBR1 →read by rule
“An orally available, small molecule antagonist of the tyrosine kinase transforming growth factor-beta (TGF-b) receptor type 1 (TGFBR1), ”NCIt, by rule
“TGF-beta receptor type I inhibitor”ChEMBL 37, by rule

Studies

All 16 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07321860Amyotrophic Lateral Sclerosis3Not yet recruitingGipfel Life SciencesJun 30, 202760
NCT02752919Healthy · United Kingdom1CompletedEli LillyJun 201640
NCT02734160Pancreatic Neoplasms · United States, France, Italy and more1CompletedEli LillyAug 2, 201837
NCT02423343Solid Tumor · United States, Spain2CompletedEli LillyDec 13, 201841
NCT02304419Neoplasms · United States1CompletedEli LillyAug 201610
NCT02240433Carcinoma, Hepatocellular · Japan1CompletedEli LillyJul 19, 20179
NCT02178358Carcinoma, Hepatocellular · China, Hong Kong, Korea, Republic of and more2CompletedEli LillyJun 30, 2017132
NCT02154646Pancreatic Neoplasms · Japan1CompletedEli LillySep 20146
NCT02008318Myelodysplastic Syndromes · Germany, Italy, Spain3CompletedEli LillyMar 201643
NCT01965808Healthy Volunteers · United States1CompletedEli LillyNov 201316
NCT01746004Healthy Volunteers · United States1CompletedEli LillyFeb 20138
NCT01722825Neoplasms · Japan1CompletedEli LillyJun 201412
NCT01682187Glioma · United States, Spain1CompletedEli LillyMay 22, 201266
NCT01582269Glioblastoma · United States, Australia, Belgium and more2CompletedEli LillyJul 26, 2014158
NCT01373164Neoplasms · United States, Belgium, France and more2CompletedEli LillyNov 2015170
NCT01246986Carcinoma, Hepatocellular · United States, Australia, France and more2CompletedEli LillyJun 6, 2019204

How it is read

Names in the registry

  • “Galunisertib”, 7 entries
  • “LY2157299”, 7 entries
  • “Galunisertib + Nerandomilast Combination”, 1 entry
  • “[^14C]-LY2157299”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.